MEDRx Co., Ltd. has been notified by its agent that the Korean Intellectual Property Office (KIPO) has granted a patent application submitted by MEDRx for an ionic liquid \( ^1 \) etodolac \( ^2 \) for use in patches.

A fundamental patent has already been granted in Korea for ETOREAT\(^{®}\), which is under development by MEDRx, for use as an external drug for the treatment of pain caused by inflammation. This patent will expire in 2025. The latest patent is an improvement patent for this fundamental patent. Grant of this patent pushes back the expiration date to 2028.

This result will have no impact on the consolidated results of operations in 2015.

<Reference>

*1: Ionic liquid
An ionic liquid is a salt with a melting point of not more than 100\(^\circ\)C and is also called a room temperature molten salt. Properties include a low melting point, high ion conductivity, high polarity, non-volatility and non-combustibility. Many applications are being examined for ionic liquids, including in solar cells and environmentally responsible reaction solvents. MEDRx was first in the world to discover that converting drugs into ionic liquids and dissolving drugs in ionic liquids can dramatically increase the transdermal permeability of these drugs. MEDRx continues to perform exclusive research activities in the field of drugs for transdermal absorption.

*2: Etodolac
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that is used extensively worldwide as an oral treatment for pain and inflammation. MEDRx’s ETOREAT\(^{®}\) is the world’s first attempt to develop a version for use as a patch.